<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137539</url>
  </required_header>
  <id_info>
    <org_study_id>MIWH08-001</org_study_id>
    <nct_id>NCT01137539</nct_id>
  </id_info>
  <brief_title>TVT-SECUR as an Office-based Procedure</brief_title>
  <acronym>TVTSOffice</acronym>
  <official_title>TVT-SECUR as an Office-based Procedure - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michigan Institution of Women's Health PC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ethicon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Michigan Institution of Women's Health PC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to assess the feasibility and success of performing the TVT-Secur in
      the office setting. Endpoints would be success, complications, and patient and physician
      acceptance of the procedure. Success would be assessed by validated questionnaires.

      This is a prospective single arm study of 50 patients who will have the TVT-Secur procedure
      done in the office under local anesthesia. They will be followed for a period of 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 50 patients who would meet the inclusion/exclusion criteria and who
      sign the informed consent. Subjects are diagnosed with Stress urinary incontinence resulting
      from urethral hypermobility with no prior urinary incontinence surgery. Subjects are women
      who no longer intend to bear children and who do not require any other concomitant surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success Based on Patient Report on Validated Questionnaire</measure>
    <time_frame>24 months</time_frame>
    <description>Negative response to question #3 on the Urogenital Distress Inventory-6 (UDI-6) questionnaire. Question #3 states, &quot;Do you currently experience urine leakage related to physical activity, coughing or sneezing.&quot; If a subject answers &quot;No&quot;, this is considered success. If a subject answers &quot;Yes&quot;, this is considered failure of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>12 months</time_frame>
    <description>Positive response to a satisfaction question</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Urinary Incontinence</condition>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Gynecare TVT-SECUR system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gynecare TVT-SECUR system</intervention_name>
    <description>All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence</description>
    <arm_group_label>Gynecare TVT-SECUR system</arm_group_label>
    <other_name>TVT-S</other_name>
    <other_name>Mid-urethral sling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stress urinary incontinence with hypermobility of the UV junction

          -  ASA I or II

          -  Age 21-89

        Exclusion Criteria:

          -  Prior anti-incontinence surgery

          -  Not completed childbearing

          -  ASA III or higher

          -  Need concomitant surgery

          -  Poor compliance for office based approach
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salil S Khandwala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan Institute of Women's Health PC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Urogynecology of Michigan PC</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <results_first_submitted>April 12, 2017</results_first_submitted>
  <results_first_submitted_qc>May 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2017</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Michigan Institution of Women's Health PC</investigator_affiliation>
    <investigator_full_name>Salil Khandwala MD</investigator_full_name>
    <investigator_title>President, Michigan Institution of Women's Health PC</investigator_title>
  </responsible_party>
  <keyword>urinary incontinence</keyword>
  <keyword>stress urinary incontinence</keyword>
  <keyword>mid-urethral slings</keyword>
  <keyword>Tension-free vaginal taping</keyword>
  <keyword>TVT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: October 2008-May 2009 at medical practice</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Gynecare TVT-SECUR System</title>
          <description>All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
Gynecare TVT-SECUR system: All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gynecare TVT-SECUR System</title>
          <description>All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
Gynecare TVT-SECUR system: All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Success Based on Patient Report on Validated Questionnaire</title>
        <description>Negative response to question #3 on the Urogenital Distress Inventory-6 (UDI-6) questionnaire. Question #3 states, &quot;Do you currently experience urine leakage related to physical activity, coughing or sneezing.&quot; If a subject answers &quot;No&quot;, this is considered success. If a subject answers &quot;Yes&quot;, this is considered failure of treatment.</description>
        <time_frame>24 months</time_frame>
        <population>46 subjects were analyzed at the 24 month period out of the total 50 subjects enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Gynecare TVT-SECUR System</title>
            <description>All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
Gynecare TVT-SECUR system: All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Success Based on Patient Report on Validated Questionnaire</title>
          <description>Negative response to question #3 on the Urogenital Distress Inventory-6 (UDI-6) questionnaire. Question #3 states, &quot;Do you currently experience urine leakage related to physical activity, coughing or sneezing.&quot; If a subject answers &quot;No&quot;, this is considered success. If a subject answers &quot;Yes&quot;, this is considered failure of treatment.</description>
          <population>46 subjects were analyzed at the 24 month period out of the total 50 subjects enrolled in the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Positive response to a satisfaction question</description>
        <time_frame>12 months</time_frame>
        <population>49 subjects were analyzed at the 12 month period out of the total 50 subjects enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Gynecare TVT-SECUR System</title>
            <description>All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
Gynecare TVT-SECUR system: All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Positive response to a satisfaction question</description>
          <population>49 subjects were analyzed at the 12 month period out of the total 50 subjects enrolled in the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data collected for 36 months following subject TVT-Secur procedure date.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gynecare TVT-SECUR System</title>
          <description>All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
Gynecare TVT-SECUR system: All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Mesh Exposure</sub_title>
                <description>1 cm x 1 cm mesh exposure noted during follow-up examination. This was managed expectantly by the principal investigator.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Salil Khandwala/Medical Director</name_or_title>
      <organization>Michigan Institute of Women's Health</organization>
      <phone>313-982-0200</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

